<DOC>
	<DOCNO>NCT01900171</DOCNO>
	<brief_summary>QGC001/1QG1 Phase I `` first time man '' study aim determine overall safety tolerability single ascend oral dos QGC001 healthy male subject compare placebo , well pharmacokinetics QGC001 metabolite EC33 pharmacodynamic property QGC001 ( effect renin-angiotensin-aldosterone system , blood pressure heart rate ) healthy male subject .</brief_summary>
	<brief_title>Phase I Study Healthy Male Subjects Comparing QGC001 Placebo</brief_title>
	<detailed_description />
	<criteria>Caucasian , male healthy subject 18 45 year age . Body weight ≥50 kg , body mass index calculate weight kg/ ( height m2 ) 18 27 kg/m2 screening . Subjects sign date inform consent form studyspecific screen procedure perform . Healthy , determine investigator basis medical history , physical examination finding , clinical laboratory test result , vital sign measurement , digital 12 lead ECG reading . Nonsmoker smoker few 5 cigarette per day determine history . Must able abstain smoking inpatient stay . Have high probability compliance completion study . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatological , haematological , neurologic , psychiatric disease history clinically important drug allergy . Acute disease state within 7 day study day 1 . History drug abuse within 1 year study day 1 . History alcoholism within 1 year day 1 . Consumption 50 g ethanol per day . Positive serologic finding human immunodeficiency virus antibody , hepatitis B surface antigen , and/or hepatitis C virus antibody . Positive finding urine drug screen ( e.g. , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates , MDMA ) History clinically important drug allergy . Prohibited Treatments : use investigational drug within 90 day prescription drug within 30 day investigational medical product administration . Consumption caffeinecontaining product excess 6 cup per day ( equivalent ) , grapefruit , grapefruitcontaining product , alcoholic beverage within 24 hour study day 1 . Use overthecounter drug include herbal supplement ( except occasional use acetaminophen [ paracetamol ] , aspirin vitamin ≤100 % recommend daily allowance ) within 7 day investigational medicinal product administration . Donation blood ( i.e . 450 ml ) within 90 day study day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>